Corixa Corporation

Glaxosmithkline Intellectual Property Development Limited

Allergy Therapeutics (uk) Limited

Christopher W Cluff

David A Johnson

Jory R Baldridge

C Gregory Sowell

Alan Worland Wheeler

Hua-Xin Gao

Gary Elliott

Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.

TLR4 agonists and compositions thereof and their use in the treatment of cancer

A method of producing a mucosal and systemic immune response in a mammal comprising administering sublingually an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said mammal.

Composition of antigen and glycolipid adjuvant for sublingual administration

Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants.

Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds

This invention provides compounds containing a 2-deoxy-2-amino-&bgr;-D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group. The invention further provides methods for inducing an immune response using the compounds of the present invention in the presence or absence of an antigen. In addition, methods for treating disease with the compounds of the present invention with or without an antigen are also provided in this invention.

Growing community of inventors

Hamilton, MT, United States of America

Christopher W Cluff